Why is Penumbra, Inc. ?
- The company has declared positive results for the last 2 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 201.5 MM
- ROCE(HY) Highest at 12.03%
- DEBT-EQUITY RATIO (HY) Lowest at -15.77 %
How much should you buy?
- Overall Portfolio exposure to Penumbra, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Penumbra, Inc. for you?
Medium Risk, High Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at USD 203.29 MM
Highest at 13.32%
Highest at 7.42 times
Highest at USD 354.69 MM
Highest at 15,185.21
Highest at USD 45.85 MM
Fallen by -0.92% (YoY
Highest at USD 894.86 MM
Lowest at -18.64 %
Highest at USD 51.33 MM
Highest at USD 52.33 MM
Highest at USD 1.17
Here's what is working for Penumbra, Inc.
Operating Cash Flows (USD MM)
Net Sales (USD MM)
Operating Profit to Interest
Net Profit (USD MM)
Debtors Turnover Ratio
Operating Profit (USD MM)
Pre-Tax Profit (USD MM)
Net Profit (USD MM)
EPS (USD)
Cash and Cash Equivalents
Debt-Equity Ratio
Raw Material Cost as a percentage of Sales






